Alnylam Pharmaceuticals
ALNY
#545
Rank
HK$296.07 B
Marketcap
HK$2,306
Share price
-1.26%
Change (1 day)
77.58%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): HK$0.54 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are HK$2.34 Billion. In 2023 the company made an earning of -HK$2.43 Billion, an increase over its 2022 earnings that were of -HK$7.55 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) HK$0.54 B-122.35%
2023 -HK$2.43 Billion-67.84%
2022 -HK$7.55 Billion36.93%
2021 -HK$5.52 Billion-8.04%
2020 -HK$6 Billion-15.66%
2019 -HK$7.11 Billion12.23%
2018 -HK$6.34 Billion62.91%
2017 -HK$3.89 Billion17.78%
2016 -HK$3.3 Billion43.44%
2015 -HK$2.31 Billion60.69%
2014 -HK$1.44 Billion98.2%
2013 -HK$0.73 Billion
2011 -HK$0.43 Billion27.48%
2010 -HK$0.34 Billion-10.92%
2009 -HK$0.38 Billion95.77%
2008 -HK$0.2 Billion
2006 -HK$0.31 Billion-9.13%
2005 -HK$0.34 Billion34.74%
2004 -HK$0.26 Billion36.79%
2003 -HK$0.19 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-HK$4.09 Billion-861.40%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$35.65 B 6,544.07%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.48 B-9.88%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$1.91 Billion-454.33%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.28 Billion-150.69%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$84.70 B 15,686.04%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$52.45 B 9,676.31%๐Ÿ‡ซ๐Ÿ‡ท France
HK$6.42 B 1,097.82%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel